Preview
Hearing Date: No hearing scheduled
Location: <>
Judge: Calendar, R
FILED
12/12/2022 10:52 AM
IRIS Y. MARTINEZ
CIRCUIT CLERK
COOK COUNTY, IL
2022L010287
2022L010287
Calendar, R
20633194
FILED DATE: 12/12/2022 10:52 AM
EXHIBIT C
Exhibit C – Motions Filed in Culverson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al.
Name of Motion Date Filed
Plaintiffs' Motion for Preferential Trial Setting 2021.08.30
2022L010287
Sanofi‐Aventis U.S. LLC, Sanofi US Services, INC., and Chattem, INC.'s Motion to Dismiss 2021.09.30.
Under 735 ILCS 5/2‐301 and 735 ILCS 5/2‐615
Walgreens Defendants' Combined 735 ILCS 5/2‐619.1 Motion to Dismiss Plaintiffs' 2021.09.30.
Complaint
FILED DATE: 12/12/2022 10:52 AM
Walgreen Defendants' Combined Motion to Dismiss Plaintiffs' Complaint 2021.09.30.
Brand Defendants' Joint Motion to Dismiss Pursuant to 735 ILCS 5/2‐615 2021.10.05.
Generic Manufacturer Defendants' Motion to Dismiss on Preemption and Other 2021.10.05.
Grounds
Defendant Patheon Manufacturing Services LLC's Memorandum of Law in Support of 2021.10.07.
Motion to Dismiss
Defendant Patheon Manufacturing Services LLC's Motion to Dismiss Plaintiffs' Claims 2021.10.07.
under 735 ILCS 5/2‐615
Boehringer Ingelheim Pharmaceuticals, et al., Confidentiality Order 2022.01.12.
Stipulation Governing the Use of Discovery Produced in the Zantac Multidistrict 2022.01.12.
Litigation (MDL No. 2924)
Boehringer Ingelheim Pharmaceuticals, et al., Protocol for Treatment of Privileged and 2022.01.12.
Work Product Materials
Generic Manufacturer Defendants' Motion to Compel Production of Settlement 2022.02.18.
Agreement Executed by Plaintiff Bayer in Prior Asbestos Action
Defendants' Motion to Sever or, in the Alternative, to Separate Plaintiffs' Claims at 2022.02.22.
Trial
Boehringer Ingelheim Pharmaceuticals, et al., Stipulation and Governing the Use of 2022.02.22.
Discovery Produced in the Zantac Multidistrict Litigation (MDL No.2924) as to Generic
Defendants
Plaintiffs' Motion for Leave to File Plaintiffs' Fourth Amended Complaint and With 2022.04.26.
Partial Redactions in Count X
Plaintiff Joseph Bayer's Renewed Motion to Compel GlaxoSmithKline LLC and 2022.06.21.
GlaxoSmithKline Holdings (Americas), Inc. to Comply with Production Requests
Plaintiffs' Motion to Re‐Consolidate Plaintiffs' Cases for Trial 2022.07.01.
Boehringer Ingelheim Pharmaceuticals, Inc. And Pfizer Inc.'s Motion for Partial 2022.07.11
Summary Judgment on Plaintiff Bayer's Claims for Alleged Defects in the Packaging,
Storage, and Transport of Zantac
Brand Defendants' Motion to Exclude Opinions of Joshua Sharlin, PH.D. 2022.07.11.
Brand Defendant's Motion to Exclude Certain Opinions of Nagi B. Kumar, PH.D. 2022.07.11.
Defendants' Brief in Support of Their Motion to Exclude Dr. Jack Goldberg's Testimony 2022.07.11.
on General and Specific Causation
Defendants' Motion to Exclude Opinions and Testimony of Gerald M. Goldhaber, PH.D. 2022.07.11.
Defendant Boehringer Ingelheim Pharmaceuticals, Inc.'s Motion for Partial Summary 2022.07.11.
Judgment on Plaintiff Bayer's Strict Liability Claims (Counts I and II)
1
Exhibit C – Motions Filed in Culverson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al.
The Brand Defendants' Motion for Summary Judgment Based on Federal Preemption 2022.07.11.
Brand Defendants' Motion for Partial Summary Judgment on Plaintiff Bayer's Counts I, 2022.07.11.
2022L010287
III, V, and VI (All Warnings‐Based Claims)
Brand Defendant's Motion for Summary Judgment Concerning Product Causation 2022.07.11.
Brand Defendants' Motion for Partial Summary Judgment on Plaintiff Bayer's Counts II, 2022.07.11.
IV, and V to the Extent Premised on a "Misbranding" Theory
FILED DATE: 12/12/2022 10:52 AM
GlaxoSmithKline LLC and GlaxoSmithKline Holdings (Americas) Inc.'s Motion for 2022.07.11.
Summary Judgment
Motion of Defendants Pfizer Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. for 2022.07.11.
Partial Summary Judgment on Plaintiff Bayer's Innovator Liability Claim (Count VI)
Defendant Pfizer's Motion for Partial Summary Judgment on Statute of Repose 2022.07.11.
Grounds (Counts I and II)
Walgreens Defendants' Motion for Summary Judgment 2022.07.11.
Brand Defendants' Motion in Limine No. 1 to Exclude Inadmissible Evidence Related to 2022.07.15.
the FDA
Defendants' Motion in Limine No. 2 to Exclude Evidence and Argument Related to the 2022.07.15.
Voluntary Recalls
Brand Defendants' Motion in Limine No. 3 to Exclude Inadmissible Evidence Related to 2022.07.15.
Other Zantac Lawsuits or Ranitidine‐Related Litigation
Defendants' Motion in Limine No. 4 to Bar Irrelevant Evidence of Defendants' Financial 2022.07.15.
Position and the Presence or Absence of Corporate Representatives
Brand Defendants' Motion in Limine to Exclude Evidence, Testimony, and Argument 2022.07.15.
that their Disclosures to the FDA were Inadequate
Defendants' Motion in Limine No. 6 to Exclude Related to Defendants' Choice of and 2022.07.15.
Decisions about Witnesses to Call
Brand Defendants' Motion in Limine No. 7 to Exclude Any Evidence or Argument 2022.07.15.
Regarding Discoloration or Odor in Ranitidine‐Hydrochloride or Finished Zantac
Product
Defendants' Motion in Limine No. 8 to Exclude Evidence, Argument, or References 2022.07.15.
Regarding Unrelated Supply Chain, Product Storage, and Product Transportation
Brand Defendants' Motion in Limine No. 9 to Exclude Material Relating to Actions 2022.07.15.
Taken by Foreign Regulatory Agencies
Walgreens' Motion in Limine No. [ ] to Preclude Plaintiff From Introducing or Eliciting 2022.07.15.
Opinion Testimony as to Certain Expert Opinions Previously Disclosed by Withdrawn
Plaintiff Expert, Zal Phiroz, MBA, PHD
Walgreens' Motion in Limine No. [ ] to Exclude Evidence, Argument, and Reference to 2022.07.15.
Any Duty by Walgreens to Test and/or Inspect Zantac for Latent or Hidden Defects
Walgreens' Motion in Limine No. [ ] to Preclude Evidence, Argument, and Reference as 2022.07.15.
to (1) What Walgreens Knew or Should Have Known About the Alleged Risk of NDMA
in Zantac/Ranitidine Products, and (2) Any Alleged Standard of Care Applicable to
Retailers
Walgreens' Motion in Limine No. [ ] to Exclude Evidence and Argument that Walgreens 2022.07.15.
Recalled or Announced a Recall of Zantac or Any Other Ranitidine‐Containing Product
2
Exhibit C – Motions Filed in Culverson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al.
Walgreens' Motion in Limine No. [ ] to Preclude Evidence, Argument, and References 2022.07.15.
to a Walgreens' Employee Recommending or Suggesting Zantac to Plaintiff
2022L010287
Boehringer Ingelheim Pharmaceuticals, Inc., et al., Joint Stipulation for Voluntary 2022.07.15.
Dismissal
Plaintiff Joseph Bayer's Omnibus Motion in Limine 2022.07.15.
Plaintiffs' Motion for Leave to File Plaintiffs' Fifth Amended Complaint and to Include 2022.07.29.
FILED DATE: 12/12/2022 10:52 AM
Prayer for Relief Seeking Punitive Damages Against GSK Defendants and Pfizer
Plaintiffs' Motion for Leave to Amend Complaint 2022.11.08.
3
Preview
Hearing Date: No hearing scheduled Location: <> Judge: Calendar, R FILED 12/12/2022 10:52 AM IRIS Y. MARTINEZ CIRCUIT CLERK COOK COUNTY, IL 2022L010287 2022L010287 Calendar, R 20633194 FILED DATE: 12/12/2022 10:52 AM EXHIBIT C Exhibit C – Motions Filed in Culverson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al. Name of Motion Date Filed Plaintiffs' Motion for Preferential Trial Setting 2021.08.30 2022L010287 Sanofi‐Aventis U.S. LLC, Sanofi US Services, INC., and Chattem, INC.'s Motion to Dismiss 2021.09.30. Under 735 ILCS 5/2‐301 and 735 ILCS 5/2‐615 Walgreens Defendants' Combined 735 ILCS 5/2‐619.1 Motion to Dismiss Plaintiffs' 2021.09.30. Complaint FILED DATE: 12/12/2022 10:52 AM Walgreen Defendants' Combined Motion to Dismiss Plaintiffs' Complaint 2021.09.30. Brand Defendants' Joint Motion to Dismiss Pursuant to 735 ILCS 5/2‐615 2021.10.05. Generic Manufacturer Defendants' Motion to Dismiss on Preemption and Other 2021.10.05. Grounds Defendant Patheon Manufacturing Services LLC's Memorandum of Law in Support of 2021.10.07. Motion to Dismiss Defendant Patheon Manufacturing Services LLC's Motion to Dismiss Plaintiffs' Claims 2021.10.07. under 735 ILCS 5/2‐615 Boehringer Ingelheim Pharmaceuticals, et al., Confidentiality Order 2022.01.12. Stipulation Governing the Use of Discovery Produced in the Zantac Multidistrict 2022.01.12. Litigation (MDL No. 2924) Boehringer Ingelheim Pharmaceuticals, et al., Protocol for Treatment of Privileged and 2022.01.12. Work Product Materials Generic Manufacturer Defendants' Motion to Compel Production of Settlement 2022.02.18. Agreement Executed by Plaintiff Bayer in Prior Asbestos Action Defendants' Motion to Sever or, in the Alternative, to Separate Plaintiffs' Claims at 2022.02.22. Trial Boehringer Ingelheim Pharmaceuticals, et al., Stipulation and Governing the Use of 2022.02.22. Discovery Produced in the Zantac Multidistrict Litigation (MDL No.2924) as to Generic Defendants Plaintiffs' Motion for Leave to File Plaintiffs' Fourth Amended Complaint and With 2022.04.26. Partial Redactions in Count X Plaintiff Joseph Bayer's Renewed Motion to Compel GlaxoSmithKline LLC and 2022.06.21. GlaxoSmithKline Holdings (Americas), Inc. to Comply with Production Requests Plaintiffs' Motion to Re‐Consolidate Plaintiffs' Cases for Trial 2022.07.01. Boehringer Ingelheim Pharmaceuticals, Inc. And Pfizer Inc.'s Motion for Partial 2022.07.11 Summary Judgment on Plaintiff Bayer's Claims for Alleged Defects in the Packaging, Storage, and Transport of Zantac Brand Defendants' Motion to Exclude Opinions of Joshua Sharlin, PH.D. 2022.07.11. Brand Defendant's Motion to Exclude Certain Opinions of Nagi B. Kumar, PH.D. 2022.07.11. Defendants' Brief in Support of Their Motion to Exclude Dr. Jack Goldberg's Testimony 2022.07.11. on General and Specific Causation Defendants' Motion to Exclude Opinions and Testimony of Gerald M. Goldhaber, PH.D. 2022.07.11. Defendant Boehringer Ingelheim Pharmaceuticals, Inc.'s Motion for Partial Summary 2022.07.11. Judgment on Plaintiff Bayer's Strict Liability Claims (Counts I and II) 1 Exhibit C – Motions Filed in Culverson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al. The Brand Defendants' Motion for Summary Judgment Based on Federal Preemption 2022.07.11. Brand Defendants' Motion for Partial Summary Judgment on Plaintiff Bayer's Counts I, 2022.07.11. 2022L010287 III, V, and VI (All Warnings‐Based Claims) Brand Defendant's Motion for Summary Judgment Concerning Product Causation 2022.07.11. Brand Defendants' Motion for Partial Summary Judgment on Plaintiff Bayer's Counts II, 2022.07.11. IV, and V to the Extent Premised on a "Misbranding" Theory FILED DATE: 12/12/2022 10:52 AM GlaxoSmithKline LLC and GlaxoSmithKline Holdings (Americas) Inc.'s Motion for 2022.07.11. Summary Judgment Motion of Defendants Pfizer Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. for 2022.07.11. Partial Summary Judgment on Plaintiff Bayer's Innovator Liability Claim (Count VI) Defendant Pfizer's Motion for Partial Summary Judgment on Statute of Repose 2022.07.11. Grounds (Counts I and II) Walgreens Defendants' Motion for Summary Judgment 2022.07.11. Brand Defendants' Motion in Limine No. 1 to Exclude Inadmissible Evidence Related to 2022.07.15. the FDA Defendants' Motion in Limine No. 2 to Exclude Evidence and Argument Related to the 2022.07.15. Voluntary Recalls Brand Defendants' Motion in Limine No. 3 to Exclude Inadmissible Evidence Related to 2022.07.15. Other Zantac Lawsuits or Ranitidine‐Related Litigation Defendants' Motion in Limine No. 4 to Bar Irrelevant Evidence of Defendants' Financial 2022.07.15. Position and the Presence or Absence of Corporate Representatives Brand Defendants' Motion in Limine to Exclude Evidence, Testimony, and Argument 2022.07.15. that their Disclosures to the FDA were Inadequate Defendants' Motion in Limine No. 6 to Exclude Related to Defendants' Choice of and 2022.07.15. Decisions about Witnesses to Call Brand Defendants' Motion in Limine No. 7 to Exclude Any Evidence or Argument 2022.07.15. Regarding Discoloration or Odor in Ranitidine‐Hydrochloride or Finished Zantac Product Defendants' Motion in Limine No. 8 to Exclude Evidence, Argument, or References 2022.07.15. Regarding Unrelated Supply Chain, Product Storage, and Product Transportation Brand Defendants' Motion in Limine No. 9 to Exclude Material Relating to Actions 2022.07.15. Taken by Foreign Regulatory Agencies Walgreens' Motion in Limine No. [ ] to Preclude Plaintiff From Introducing or Eliciting 2022.07.15. Opinion Testimony as to Certain Expert Opinions Previously Disclosed by Withdrawn Plaintiff Expert, Zal Phiroz, MBA, PHD Walgreens' Motion in Limine No. [ ] to Exclude Evidence, Argument, and Reference to 2022.07.15. Any Duty by Walgreens to Test and/or Inspect Zantac for Latent or Hidden Defects Walgreens' Motion in Limine No. [ ] to Preclude Evidence, Argument, and Reference as 2022.07.15. to (1) What Walgreens Knew or Should Have Known About the Alleged Risk of NDMA in Zantac/Ranitidine Products, and (2) Any Alleged Standard of Care Applicable to Retailers Walgreens' Motion in Limine No. [ ] to Exclude Evidence and Argument that Walgreens 2022.07.15. Recalled or Announced a Recall of Zantac or Any Other Ranitidine‐Containing Product 2 Exhibit C – Motions Filed in Culverson v. Boehringer Ingelheim Pharmaceuticals, Inc. et al. Walgreens' Motion in Limine No. [ ] to Preclude Evidence, Argument, and References 2022.07.15. to a Walgreens' Employee Recommending or Suggesting Zantac to Plaintiff 2022L010287 Boehringer Ingelheim Pharmaceuticals, Inc., et al., Joint Stipulation for Voluntary 2022.07.15. Dismissal Plaintiff Joseph Bayer's Omnibus Motion in Limine 2022.07.15. Plaintiffs' Motion for Leave to File Plaintiffs' Fifth Amended Complaint and to Include 2022.07.29. FILED DATE: 12/12/2022 10:52 AM Prayer for Relief Seeking Punitive Damages Against GSK Defendants and Pfizer Plaintiffs' Motion for Leave to Amend Complaint 2022.11.08. 3